MCID: INT068
MIFTS: 53

Intestinal Disease

Categories: Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Intestinal Disease

MalaCards integrated aliases for Intestinal Disease:

Name: Intestinal Disease 12 15 17
Intestinal Diseases 44 70

Classifications:



External Ids:

Disease Ontology 12 DOID:5295
ICD9CM 34 569.9
MeSH 44 D007410
NCIt 50 C26801
SNOMED-CT 67 266483008
ICD10 32 K63.9
UMLS 70 C0021831

Summaries for Intestinal Disease

Disease Ontology : 12 A gastrointestinal system disease that is located in the intestine.

MalaCards based summary : Intestinal Disease, also known as intestinal diseases, is related to inflammatory bowel disease and crohn's disease, and has symptoms including constipation, diarrhea and signs and symptoms, digestive. An important gene associated with Intestinal Disease is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are MicroRNAs in cancer and IgA-Producing B Cells in the Intestine. The drugs Prucalopride and Copper have been mentioned in the context of this disorder. Affiliated tissues include intestine, colon and small intestine.

Wikipedia : 73 The gastrointestinal tract, (GI tract, GIT, digestive tract, digestion tract, alimentary canal) is the... more...

Related Diseases for Intestinal Disease

Diseases in the Intestinal Disease family:

Chronic Intestinal Failure Congenital Intestinal Disease Due to an Enzymatic Defect
Intestinal Disease Due to Fat Malabsorption Intestinal Disease Due to Vitamin Absorption Anomaly
Rare Intestinal Disease

Diseases related to Intestinal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 557)
# Related Disease Score Top Affiliating Genes
1 inflammatory bowel disease 32.4 TP53 TFF3 MIR21 ICOSLG GHRL GCG
2 crohn's disease 32.2 ICOSLG GCG DEFB4A CCR6
3 colonic disease 32.2 TP53 MIR31 MIR21 MIR199A1 MIR196A1 MIR17
4 celiac disease 1 31.1 ICOSLG H2AC18 GHRL GCG CCR6
5 gastrointestinal system disease 31.0 MIR518A1 MIR31 MIR21 MIR199A1 MIR196A1 MIR17
6 gastritis 30.9 TP53 GHRL DEFB4A CCR6
7 lymphoma, mucosa-associated lymphoid type 30.8 TP53 SDC1 ICOSLG CCR6 BCL6
8 peptic ulcer disease 30.8 TP53 GHRL DEFB4A
9 diffuse large b-cell lymphoma 30.7 TP53 SDC1 MIR21 MIR199A1 MIR17 MIR145
10 disease by infectious agent 30.7 MIR21 MIR199A1 MIR196A1 MIR17 MIR126 ICOSLG
11 immune deficiency disease 30.7 MIR21 MIR199A1 MIR196A1 MIR17 MIR126 ICOSLG
12 marginal zone b-cell lymphoma 30.6 SDC1 CCR6 BCL6
13 cholangitis, primary sclerosing 30.6 MIR199A1 ICOSLG CCR6
14 intestinal benign neoplasm 30.5 TP53 MIR21 MIR199A1 MIR196A1 MIR17 MIR145
15 eye disease 30.5 TP53 SDC1 MIR21 MIR199A1 MIR196A1 MIR17
16 pancreatic ductal adenocarcinoma 30.5 TP53 MIR31 MIR21 MIR199A1 MIR196A1 MIR145
17 vascular disease 30.5 TP53 MIR21 MIR199A1 MIR145 MIR143 MIR126
18 pulmonary disease, chronic obstructive 30.5 MIR21 MIR199A1 MIR17 MIR126 ICOSLG H2AC18
19 prostate disease 30.5 MIR31 MIR21 MIR199A1 MIR196A1 MIR17 MIR145
20 kidney cancer 30.5 TP53 MIR21 MIR199A1 MIR17 MIR126
21 pancreatic cancer 30.5 TP53 MIR31 MIR21 MIR199A1 MIR196A1 MIR17
22 barrett esophagus 30.5 TP53 TFF3 MIR196A1 APC
23 lymphoma, non-hodgkin, familial 30.4 TP53 SDC1 MIR31 MIR21 MIR199A1 MIR196A1
24 non-alcoholic fatty liver disease 30.4 TP53 MIR31 MIR21 MIR199A1 MIR17 MIR126
25 ovarian disease 30.4 TP53 MIR21 MIR199A1 MIR17 MIR145 MIR143
26 colorectal adenoma 30.4 TP53 MIR21 MIR17 APC
27 esophageal cancer 30.4 TP53 MIR31 MIR21 MIR199A1 MIR196A1 MIR145
28 coccidiosis 30.4 ICOSLG H2AC18 CCR6
29 gastric cancer 30.3 TP53 TFF3 MIR21 MIR199A1 MIR17 MIR145
30 endometriosis 30.3 MIR199A1 MIR145 MIR143 MIR126
31 deficiency anemia 30.3 ICOSLG H2AC18 GHRL CCR6 APC
32 non-alcoholic steatohepatitis 30.2 TP53 MIR21 GHRL
33 colorectal cancer 30.1 TP53 TFF3 MIR31 MIR21 MIR199A1 MIR196A1
34 colitis 29.9 TFF3 ICOSLG DEFB4A CCR6
35 alpha-heavy chain disease 11.4
36 alpha chain disease 11.0
37 protozoal dysentery 11.0
38 cystoisosporiasis 11.0
39 rare intestinal disease 11.0
40 genetic intestinal disease 10.9
41 genetic intestinal disease due to fat malabsorption 10.9
42 congenital intestinal disease due to an enzymatic defect 10.9
43 intestinal disease due to fat malabsorption 10.9
44 intestinal disease due to vitamin absorption anomaly 10.9
45 irritable bowel syndrome 10.9
46 short bowel syndrome 10.9
47 enterokinase deficiency 10.8
48 epilepsy with bilateral occipital calcifications 10.8
49 gastrointestinal defects and immunodeficiency syndrome 10.8
50 bile acid synthesis defect, congenital, 1 10.8

Comorbidity relations with Intestinal Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Esophagitis
Heart Disease Intestinal Obstruction
Paralytic Ileus

Graphical network of the top 20 diseases related to Intestinal Disease:



Diseases related to Intestinal Disease

Symptoms & Phenotypes for Intestinal Disease

UMLS symptoms related to Intestinal Disease:


constipation; diarrhea; signs and symptoms, digestive; anal or rectal pain

Drugs & Therapeutics for Intestinal Disease

Drugs for Intestinal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 330)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prucalopride Approved Phase 4 179474-81-8
2
Copper Approved, Investigational Phase 4 7440-50-8 27099
3
Tocopherol Approved, Investigational Phase 4 1406-66-2
4
Albendazole Approved, Vet_approved Phase 4 54965-21-8 2082
5
Lactulose Approved Phase 4 4618-18-2 11333
6
Piperazine Approved, Vet_approved Phase 4 110-85-0 4837
7
Mebendazole Approved, Vet_approved Phase 4 31431-39-7 4030
8
Sodium citrate Approved, Investigational Phase 4 68-04-2
9
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
10
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
11
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
12
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
13
Ibuprofen Approved Phase 4 15687-27-1 3672
14
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
15
Racepinephrine Approved Phase 4 329-65-7 838
16
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
17
Simethicone Approved Phase 4 8050-81-5
18
Fidaxomicin Approved Phase 4 873857-62-6
19
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
20
Ondansetron Approved Phase 4 99614-02-5 4595
21
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
22
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
23
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
24
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
25
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
26
Ustekinumab Approved, Investigational Phase 4 815610-63-0
27
Budesonide Approved Phase 4 51333-22-3 63006 5281004
28
Adalimumab Approved, Experimental Phase 4 331731-18-1 16219006
29
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
30
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
31
Infliximab Approved Phase 4 170277-31-3
32
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
33
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
34 Tocotrienol Investigational Phase 4 6829-55-6
35 Serotonin Receptor Agonists Phase 4
36 Copper Supplement Phase 4
37 Tocotrienols Phase 4
38 Tocopherols Phase 4
39 Adrenergic alpha-Agonists Phase 4
40 Adrenergic Agonists Phase 4
41 Anesthetics Phase 4
42 Antacids Phase 4
43 Anti-Ulcer Agents Phase 4
44 Mydriatics Phase 4
45 Adrenergic Agents Phase 4
46 Anti-Inflammatory Agents, Non-Steroidal Phase 4
47 Analgesics Phase 4
48 Analgesics, Non-Narcotic Phase 4
49 Citrate Phase 4
50 DMP 777 Phase 4 157341-41-8

Interventional clinical trials:

(show top 50) (show all 706)
# Name Status NCT ID Phase Drugs
1 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
2 Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section Unknown status NCT02571881 Phase 4 Oxycodone;oxycodone-naloxone
3 The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
4 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
5 Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome Unknown status NCT01312259 Phase 4
6 Prospective Trial Comparing Push-and-Pull Enteroscopy With the Single- and Double-Balloon Techniques in Patients With Obscure Small-Bowel Bleeding Unknown status NCT01176864 Phase 4
7 Prospective Trial Comparing Single-Operator and Dual-Operator Double-balloon Endoscopy in Patients With Small-Bowel Disorders Unknown status NCT01184690 Phase 4
8 Evaluating the Efficacy of Weekly Folic Acid in Pediatric Inflammatory Bowel Disease Patients on Methotrexate Unknown status NCT03860012 Phase 4 Folic Acid
9 Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth Completed NCT01748929 Phase 4 Albendazole;Placebo
10 Effect of Intestinal Helminths on Gut Microflora Completed NCT01192802 Phase 4 albendazole;albendazole;albendazole
11 Improving Early Childhood Growth and Development in Resource-poor LMICs by Incorporating Deworming in Integrated Child Health Care Completed NCT01314937 Phase 4 Mebendazole
12 Double-Blind, Placebo-Controlled, Randomized Two-Week Study, Comparing Small Bowel Lesions Associated With Celecoxib (200 mg BID) vs. Ibuprofen (800 mg TID) Plus Omeprazole (20 mg QD) Completed NCT00640809 Phase 4 Celecoxib;Ibuprofen plus Omeprazole
13 A Prospective Randomized Trial of Transversus Abdominis Plane (TAP) INtraoperative Block With Bupivacaine/Dexamethasone aGainst Liposomal Bupivacaine (Exparel®): the TINGLE Trial Completed NCT03723447 Phase 4 Liposomal bupivacaine;Bupivacaine/epinephrine/dexamethasone
14 The Best Dosage and Timing of PEG for Bowel Preparation Before Capsule Endoscopy a Prospective, Single-Blind, Randomized, Multi-center Study Completed NCT02486536 Phase 4 polyethylene glycol
15 Randomized Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients Completed NCT02461758 Phase 4
16 Open Label Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) Completed NCT02437591 Phase 4 fidaxomicin
17 Mode of Action of Ondansetron, a 5-HT Receptor 3 Antagonist, in Lactulose Induced Diarrhoea Completed NCT03833999 Phase 4 Ondansetron 8mg;Lactulose;Placebo oral capsule
18 Opioid Induced Bowel Dysfunction in Patients Undergoing Spinal Surgery Completed NCT02573922 Phase 4 oxycodone-naloxone;Oxycodone
19 Precision Dosing Versus Conventional Dosing of Infliximab Maintenance Therapy: a Randomized Controlled Multicenter Study in Patients With IBD in Clinical Remission Completed NCT02453776 Phase 4 PRECISION dosing Infliximab
20 A Randomised Controlled Trial Comparing the Efficacy of Intravenous Iron Sucrose and Oral Iron Sulfate in Patients With Iron Deficiency. Completed NCT01067547 Phase 4 Iron Sucrose.;Iron sucrose
21 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
22 Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease Completed NCT01341808 Phase 4
23 Colon Cleasing for Colonoscopy in Patients With IBD Colitis: Efficacy and Acceptability of 4 Liter PEG vs 2 Liter PEG Plus Bisacodil Completed NCT02248337 Phase 4 Colon preparation for colonoscopy
24 A Double Blind Randomized Controlled Trial of High Volume Simethicone to Improve Visualization During Capsule Endoscopy Completed NCT02334631 Phase 4 High Volume Simethicone;Standard Volume Simethicone
25 Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point-of-care-testing in Inflammatory Bowel Disease: a Pragmatic Trial Completed NCT04775732 Phase 4
26 Nurse Administered Propofol Sedation vs. Standard Therapy for Colonoscopy in Patients With IBD. A Randomised Controlled Study on Satisfaction and Adherence to Treatment Program. Completed NCT01934088 Phase 4 Propofol;Midazolam;Fentanyl
27 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
28 The Influence of 5-Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
29 Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease: A Novel Adjunctive Therapy for Chronic Inflammatory Illness Completed NCT02162862 Phase 4 bupropion-SR
30 Influence of Immunosuppressive Treatment on Immunological Response to Pneumococcal Conjugated Vaccine (PCV13) in Patients With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
31 Chronotherapy in Inflammatory Bowel Disease Recruiting NCT04304950 Phase 4 Evening Group;Morning Group
32 A Pilot Study Evaluating Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab Recruiting NCT03798691 Phase 4
33 De-escalation of Anti-TNF Therapy in Adolescents and Young Adults With IBD With Tight Faecal Calprotectin and Trough Level Monitoring Recruiting NCT04646187 Phase 4
34 Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD). Recruiting NCT04626947 Phase 4
35 Identification of Predictive Biomarkers for Response to Biologic Therapies in Inflammatory Bowel Disease by Proteomic and Mass Cytometry Approaches Recruiting NCT03885713 Phase 4
36 Efficacy and Safety of Standardized Fecal Microbiota Transplantation for Moderate to Severe Crohn&Apos;s Diseases Recruiting NCT01793831 Phase 4
37 Open-label Withdrawal Trial of Budesonide in Patients With Immune Mediated Enteropathies Recruiting NCT03866538 Phase 4 Withdrawal of Oral Budesonide
38 Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: Multicentre, Prospective, Randomized Clinical Trial and Economic Evaluation Active, not recruiting NCT02994836 Phase 4 Anti-TNF discontinuation: Physiological saline solution;Anti-TNF discontinuation: Physiological saline solution
39 Stricture Definition and Treatment (STRIDENT) Drug Therapy Study Active, not recruiting NCT03220841 Phase 4 Adalimumab Injection;Thiopurine
40 An Assessor-blinded, Randomized, Controlled, Single Center, Parallel Design Trial With Patient Masking to Compare Early Postoperative Gastric Emptying Associated With Rocuronium Neuromuscular Reversal With Sugammadex Versus Neostigmine in Adults Undergoing Colon and Rectal Surgery Not yet recruiting NCT04546672 Phase 4 Sugammadex;Neostigmine
41 A Phase 4, Multicenter, Open-label Study of Serum Infliximab Concentrations and Efficacy and Safety of Dose Escalation in Pediatric Patients With Inflammatory Bowel Disease Terminated NCT02566889 Phase 4 Infliximab
42 Pilot Study of the Role of PET-CT for Diagnosis and Assessment of Therapeutic Efficacy in Inflammatory Bowel Disease Terminated NCT00205062 Phase 4
43 Thiopurine Induced Pancreatitis in IBD Patients Withdrawn NCT02281799 Phase 4 Azathioprine
44 Prospective Experimental of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission Unknown status NCT02044952 Phase 2, Phase 3 Mesalazine, Tripterygium glycosides
45 A Randomized, Double-blind, Independent 3rd Party Unblind, Active-controlled, Parallel-group, Multi-center Trial, in Contrast With Anisodamine (654-II), 10mg, to Evaluate the Efficacy and Safety of Buscopan® Solution for Injection, 20mg (Intramuscularly) for the Treatment of Acute Gastric or Intestinal Spasm-like Pain Completed NCT01929044 Phase 3 654-II (anisodamine);Buscopan® (hyoscine butylbromide)
46 Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh Completed NCT01375647 Phase 3
47 A Prospective, Randomized, Parallel, Multi-center, Phase 3 Trial to Evaluate Safety and Efficacy of PBK-1701TC Completed NCT03509220 Phase 3 PBK-1701TC;Standard oral preparation
48 Randomized Controlled Double-blind Vs. Placebo Multicentre Study on the Safety and Effectiveness of Thalidomide in the Treatment of Refractory Crohn's Disease and Ulcerative Colitis. Completed NCT00720538 Phase 3 Thalidomide;placebo
49 The Home Telemanagement (UC HAT) Trial for Patients With Ulcerative Colitis Completed NCT00620126 Phase 3
50 A Prospective, Non-controlled, Safety Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease (PROMISE) Completed NCT01599702 Phase 3 Iron Isomaltoside 1000

Search NIH Clinical Center for Intestinal Disease

Cochrane evidence based reviews: intestinal diseases

Genetic Tests for Intestinal Disease

Anatomical Context for Intestinal Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Intestinal Disease:

19
Intestine

MalaCards organs/tissues related to Intestinal Disease:

40
Colon, Small Intestine, Bone, Liver, Skin, Neutrophil, Heart

Publications for Intestinal Disease

Articles related to Intestinal Disease:

(show top 50) (show all 4389)
# Title Authors PMID Year
1
Effects of short chain fatty acids on metabolic and inflammatory processes in human health. 61
33571672 2021
2
The dark side of the gut: Virome-host interactions in intestinal homeostasis and disease. 61
33760921 2021
3
A review of dietary phytochemicals and their relation to oxidative stress and human diseases. 61
33445014 2021
4
2,3,5,4'-Tetrahydroxystilbene-2-O-β-D-glucoside, a major bioactive component from Polygoni multiflori Radix (Heshouwu) suppresses DSS induced acute colitis in BALb/c mice by modulating gut microbiota. 61
33761623 2021
5
Simulation modelling to estimate the herd-sensitivity of various pool sizes to test beef herds for Johne's disease in Australia. 61
33667760 2021
6
Aquaporin: targets for dietary nutrients to regulate intestinal health. 61
33811387 2021
7
Coptis chinensis Franch polysaccharides provide a dynamically regulation on intestinal microenvironment, based on the intestinal flora and mucosal immunity. 61
33152428 2021
8
Paneth cells: Maintaining dynamic microbiome-host homeostasis, protecting against inflammation and cancer. 61
33244814 2021
9
Protective function of surface layer protein from Lactobacillus casei fb05 against intestinal pathogens in vitro. 61
33561743 2021
10
Shiga toxin-producing Escherichia coli isolated from pasteurized dairy products from Bahia, Brazil. 61
33741165 2021
11
The NLRP6 inflammasome. 61
33314083 2021
12
Historical Perspective: Metchnikoff and the intestinal microbiome. 61
33630385 2021
13
High animal protein diet and gut microbiota in human health. 61
33724115 2021
14
Beta-Glucuronidase Inhibition by Constituents of Mulberry Bark. 61
33733438 2021
15
A myeloid-stromal niche and gp130 rescue in NOD2-driven Crohn's disease. 61
33789339 2021
16
Review article: investigation and management of internal fistulae in Crohn's disease. 61
33721351 2021
17
Clostridium perfringens Produces an Adhesive Pilus Required for the Pathogenesis of Necrotic Enteritis in Poultry. 61
33468589 2021
18
Contributions of HO-1-Dependent MAPK to Regulating Intestinal Barrier Disruption. 61
33093265 2021
19
The emerging role of ferroptosis in intestinal disease. 61
33731703 2021
20
Functions of Dendritic Cells and Its Association with Intestinal Diseases. 61
33800865 2021
21
Human gut-associated lymphoid tissues (GALT); diversity, structure, and function. 61
33753873 2021
22
Sodium houttuyfonate attenuates dextran sulfate sodium associated colitis precolonized with Candida albicans through inducing β-glucan exposure. 61
33682190 2021
23
Ocular manifestations of inflammatory bowel diseases: an update for gastroenterologists. 61
32677418 2021
24
Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study. 61
33767028 2021
25
Effects of Intestinal Fungi and Viruses on Immune Responses and Inflammatory Bowel Diseases. 61
33347881 2021
26
A systematic review of gut microbiome and ocular inflammatory diseases: Are they associated? 61
33595467 2021
27
Deletion of mucin 2 induces colitis with concomitant metabolic abnormalities in mice. 61
33728986 2021
28
Small Intestinal Hemangioma: A Case Report. 61
33774648 2021
29
Posttranslational modifications as therapeutic targets for intestinal disorders. 61
33412276 2021
30
Doppler ultrasound assessment of splanchnic perfusion and heart rate for the detection of necrotizing enterocolitis. 61
33580271 2021
31
Urine-derived extracellular vesicle miRNAs as possible biomarkers for and mediators of necrotizing enterocolitis: A proof of concept study. 61
33785202 2021
32
Transversal gene expression panel to evaluate intestinal health in broiler chickens in different challenging conditions. 61
33737699 2021
33
Fusobacterium nucleatum impedes remission of colitis in a mouse model. 61
33674867 2021
34
Features of Intestinal Disease Associated With COVID-Related Multisystem Inflammatory Syndrome in Children. 61
32969960 2021
35
Role of melatonin in murine "restraint stress"-induced dysfunction of colonic microbiota. 61
33630247 2021
36
Protective effect of naringin on small intestine injury in NSAIDs related enteropathy by regulating ghrelin/GHS-R signaling pathway. 61
33333047 2021
37
Molecular detection and subtype distribution of Blastocystis in farmed pigs in southern China. 61
33482261 2021
38
Pediococcus pentosaceus ZJUAF-4 relieves oxidative stress and restores the gut microbiota in diquat-induced intestinal injury. 61
33475796 2021
39
Metabolic Regulation of Intestinal Stem Cell Homeostasis. 61
33648839 2021
40
Indole-3-propionic Acid Improved the Intestinal Barrier by Enhancing Epithelial Barrier and Mucus Barrier. 61
33356219 2021
41
Quantitative microbial risk assessment of bioaerosols in a wastewater treatment plant by using two aeration modes. 61
33051848 2021
42
Safety and efficacy of small-bowel capsule endoscopy examination in patients with Billroth II gastrojejunostomy. 61
33547490 2021
43
NDRG2 is expressed on enteric glia and altered in conditions of inflammation and oxygen glucose deprivation/reoxygenation. 61
33205345 2021
44
Research progress and challenges to coronavirus vaccine development. 61
32936465 2021
45
Human placental-derived stem cell therapy ameliorates experimental necrotizing enterocolitis. 61
33566727 2021
46
Prospecting Human Milk Oligosaccharides as a Defense Against Viral Infections. 61
33470804 2021
47
Histopathology of Non-IBD Colitis. A practical approach from the Italian Group for the study of the gastrointestinal tract (GIPAD). 61
33686310 2021
48
Homozygous n.64C>T mutation in mitochondrial RNA-processing endoribonuclease gene causes cartilage hair hypoplasia syndrome in two siblings. 61
33444820 2021
49
Patterns of Immune Dysregulation in Primary Immunodeficiencies: A Systematic Review. 61
33186766 2021
50
Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies. 61
33640469 2021

Variations for Intestinal Disease

Copy number variations for Intestinal Disease from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 37762 1 94500000 107000000 Gain AMY1A Intestinal disease
2 37786 1 94700000 107200000 Loss AMY1A Intestinal disease
3 84156 14 23788159 23802256 Insertion TGM1 Intestinal disease

Expression for Intestinal Disease

Search GEO for disease gene expression data for Intestinal Disease.

Pathways for Intestinal Disease

Pathways related to Intestinal Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.77 TP53 MIR31 MIR21 MIR199A1 MIR17 MIR145
2 10.95 ICOSLG CCR6 BCL6
3 10.27 MIR199A1 MIR145

GO Terms for Intestinal Disease

Cellular components related to Intestinal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.32 TFF3 MIR31 MIR21 MIR199A1 MIR17 MIR143

Biological processes related to Intestinal Disease according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.99 TP53 MIR21 GHRL GCG BCL6
2 positive regulation of protein kinase B signaling GO:0051897 9.84 MIR126 MIR143 MIR199A1 MIR21
3 negative regulation of inflammatory response GO:0050728 9.73 GHRL MIR126 MIR145 MIR31
4 negative regulation of angiogenesis GO:0016525 9.71 GHRL MIR143 MIR145 MIR21
5 positive regulation of blood vessel endothelial cell migration GO:0043536 9.7 MIR126 MIR143 MIR31
6 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.63 MIR145 MIR199A1 MIR21
7 miRNA mediated inhibition of translation GO:0035278 9.62 MIR145 MIR17 MIR21 MIR31
8 positive regulation of histone deacetylation GO:0031065 9.58 TP53 BCL6
9 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.58 MIR17 MIR199A1
10 angiotensin-activated signaling pathway GO:0038166 9.57 MIR143 MIR145
11 positive regulation of metalloendopeptidase activity GO:1904685 9.56 MIR17 MIR21
12 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.55 MIR17 MIR21
13 positive regulation of sprouting angiogenesis GO:1903672 9.54 GHRL MIR126 MIR31
14 aorta smooth muscle tissue morphogenesis GO:0060414 9.51 MIR143 MIR145
15 regulation of phenotypic switching GO:1900239 9.49 MIR143 MIR145
16 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.48 MIR143 MIR17
17 positive regulation of angiogenesis GO:0045766 9.35 MIR126 MIR143 MIR199A1 MIR21 MIR31
18 positive regulation of vascular endothelial cell proliferation GO:1905564 9.33 GHRL MIR126 MIR21
19 gene silencing by miRNA GO:0035195 9.28 MIR126 MIR143 MIR145 MIR17 MIR196A1 MIR199A1
20 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.26 MIR143 MIR145

Molecular functions related to Intestinal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.5 MIR126 MIR143 MIR145 MIR17 MIR21 MIR31
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.28 MIR126 MIR143 MIR145 MIR17 MIR196A1 MIR199A1

Sources for Intestinal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....